Saturday 17 October 2026
Export AKTX’s income statement to Excel — free account
Akari Therapeutics PLC
AKTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 60.3%, free cash flow grew 4.51% and total debt fell 1.00%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
8.18
0.66
−7.47%
Follow AKTX
Akari Therapeutics PLC (AKTX) P/E ratio
Akari Therapeutics PLC has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 17.3× (October 2016) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 17.3×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DARE Dare Bioscience, Inc. compare | n/m |
| GTBP GT Biopharma, Inc. compare | n/m |
| MRKR MARKER THERAPEUTICS, INC. compare | n/m |
| TCRX TScan Therapeutics, Inc. compare | n/m |
| AKTX Akari Therapeutics PLC | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| VAXX Vaxxinity, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | 0.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)